Kyahn Williamson - Telix Pharmaceuticals Sr Relations
| TLPPF Stock | USD 14.06 0.06 0.43% |
Insider
Kyahn Williamson is Sr Relations of Telix Pharmaceuticals Limited
| Phone | 61 3 3093 3897 |
| Web | https://telixpharma.com |
Telix Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4111) % which means that it has lost $0.4111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5507) %, meaning that it generated substantial loss on money invested by shareholders. Telix Pharmaceuticals' management efficiency ratios could be used to measure how well Telix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Yong MD | Innovent Biologics | 54 | |
| Brian Min | Genscript Biotech | N/A | |
| Jeff Fairman | Vaxcyte | 60 | |
| Christopher MD | Arcellx | 44 | |
| Simon MBBS | Keros Therapeutics | 54 | |
| Melissa MBA | Zentalis Pharmaceuticals Llc | 45 | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Ashish MBA | Vaxcyte | 52 | |
| Hao Ede | Innovent Biologics | 64 | |
| Prof MD | Ventyx Biosciences | N/A | |
| John Nuss | Ventyx Biosciences | 65 | |
| Rami Elghandour | Arcellx | 45 | |
| Sergei Gryaznov | MAIA Biotechnology | 64 | |
| Annelise Vuidepot | Immunocore Holdings | N/A | |
| Anna Mowry | Nautilus Biotechnology | 40 | |
| Zhenyu Liu | Genscript Biotech | 46 | |
| Jasbir Seehra | Keros Therapeutics | 68 | |
| Christopher MSc | Keros Therapeutics | 50 | |
| Grant MBA | Vaxcyte | 56 | |
| Blake Salisbury | Innovent Biologics | N/A | |
| Brian MBA | Immunocore Holdings | 57 | |
Management Performance
| Return On Equity | -1.55 | |||
| Return On Asset | -0.41 |
Telix Pharmaceuticals Leadership Team
Elected by the shareholders, the Telix Pharmaceuticals' board of directors comprises two types of representatives: Telix Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telix. The board's role is to monitor Telix Pharmaceuticals' management team and ensure that shareholders' interests are well served. Telix Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telix Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jyoti BappSc, Chief APAC | ||
| Meredith Crowe, Interim Culture | ||
| BSc BSc, Chief Scientist | ||
| Christian Davis, EMEA Marketing | ||
| Andreas MD, Chief Director | ||
| Amanda Griffin, Communications Mang | ||
| BEng DPhil, Group CoFounder | ||
| Kyahn Williamson, Sr Relations | ||
| BBus FCPA, Group Officer | ||
| Lena MoranAdams, G Counsel | ||
| AGIA ACG, Risk Governance |
Telix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Telix Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.55 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (3.95) % | |||
| Current Valuation | 1.39 B | |||
| Shares Outstanding | 317.02 M | |||
| Shares Owned By Insiders | 27.60 % | |||
| Shares Owned By Institutions | 13.59 % | |||
| Price To Book | 21.16 X | |||
| Price To Sales | 52.21 X | |||
| Revenue | 4.9 M |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Telix Pink Sheet
When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.